Centrosomes and myeloma; aneuploidy and proliferation

Wee J. Chng, Rafael Fonseca

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Multiple myeloma is the second most common hematological malignancy in the United States. The disease is characterized by an accumulation of clonal plasma cells. Clinically, patients present with anemia, lytic bone lesions, hypercalcaemia, or renal impairment. The genome of the malignant plasma cells is extremely unstable and is typically aneuploid and characterized by a complex combination of structure and numerical abnormalities. The basis of the genomic instability underlying myeloma is unclear. In this regard, centrosome amplification is present in about a third of myeloma and may represent a mechanism leading to genomic instability in myeloma. Centrosome amplification is associated with high-risk features and poor prognosis. Understanding the underlying etiology of centrosome amplification in myeloma may lead to new therapeutic avenues.

Original languageEnglish (US)
Pages (from-to)697-707
Number of pages11
JournalEnvironmental and Molecular Mutagenesis
Volume50
Issue number8
DOIs
StatePublished - Oct 2009

Fingerprint

Centrosome
Aneuploidy
Genomic Instability
Plasma Cells
Hypercalcemia
Hematologic Neoplasms
Multiple Myeloma
Anemia
Genome
Kidney
Bone and Bones
Therapeutics

Keywords

  • Aneuploidy
  • Centrosomes
  • Genetics
  • Myeloma

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Epidemiology
  • Genetics(clinical)

Cite this

Centrosomes and myeloma; aneuploidy and proliferation. / Chng, Wee J.; Fonseca, Rafael.

In: Environmental and Molecular Mutagenesis, Vol. 50, No. 8, 10.2009, p. 697-707.

Research output: Contribution to journalArticle

@article{c4bc8778edd645f191aaa7ecedf1736f,
title = "Centrosomes and myeloma; aneuploidy and proliferation",
abstract = "Multiple myeloma is the second most common hematological malignancy in the United States. The disease is characterized by an accumulation of clonal plasma cells. Clinically, patients present with anemia, lytic bone lesions, hypercalcaemia, or renal impairment. The genome of the malignant plasma cells is extremely unstable and is typically aneuploid and characterized by a complex combination of structure and numerical abnormalities. The basis of the genomic instability underlying myeloma is unclear. In this regard, centrosome amplification is present in about a third of myeloma and may represent a mechanism leading to genomic instability in myeloma. Centrosome amplification is associated with high-risk features and poor prognosis. Understanding the underlying etiology of centrosome amplification in myeloma may lead to new therapeutic avenues.",
keywords = "Aneuploidy, Centrosomes, Genetics, Myeloma",
author = "Chng, {Wee J.} and Rafael Fonseca",
year = "2009",
month = "10",
doi = "10.1002/em.20528",
language = "English (US)",
volume = "50",
pages = "697--707",
journal = "Environmental and Molecular Mutagenesis",
issn = "0893-6692",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Centrosomes and myeloma; aneuploidy and proliferation

AU - Chng, Wee J.

AU - Fonseca, Rafael

PY - 2009/10

Y1 - 2009/10

N2 - Multiple myeloma is the second most common hematological malignancy in the United States. The disease is characterized by an accumulation of clonal plasma cells. Clinically, patients present with anemia, lytic bone lesions, hypercalcaemia, or renal impairment. The genome of the malignant plasma cells is extremely unstable and is typically aneuploid and characterized by a complex combination of structure and numerical abnormalities. The basis of the genomic instability underlying myeloma is unclear. In this regard, centrosome amplification is present in about a third of myeloma and may represent a mechanism leading to genomic instability in myeloma. Centrosome amplification is associated with high-risk features and poor prognosis. Understanding the underlying etiology of centrosome amplification in myeloma may lead to new therapeutic avenues.

AB - Multiple myeloma is the second most common hematological malignancy in the United States. The disease is characterized by an accumulation of clonal plasma cells. Clinically, patients present with anemia, lytic bone lesions, hypercalcaemia, or renal impairment. The genome of the malignant plasma cells is extremely unstable and is typically aneuploid and characterized by a complex combination of structure and numerical abnormalities. The basis of the genomic instability underlying myeloma is unclear. In this regard, centrosome amplification is present in about a third of myeloma and may represent a mechanism leading to genomic instability in myeloma. Centrosome amplification is associated with high-risk features and poor prognosis. Understanding the underlying etiology of centrosome amplification in myeloma may lead to new therapeutic avenues.

KW - Aneuploidy

KW - Centrosomes

KW - Genetics

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=70349902608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349902608&partnerID=8YFLogxK

U2 - 10.1002/em.20528

DO - 10.1002/em.20528

M3 - Article

C2 - 19739237

AN - SCOPUS:70349902608

VL - 50

SP - 697

EP - 707

JO - Environmental and Molecular Mutagenesis

JF - Environmental and Molecular Mutagenesis

SN - 0893-6692

IS - 8

ER -